Ocular Therapeutix: 2022 Dextenza revenue est. $50.2M (+20% YoY); cash $102.3M; pipeline on track

OCULAR THERAPEUTIX, INC

2022-FY EPS reported -$0.97 revenue$51,494,000

Dextenza net product revenue: Q4 2022 est. $13.6M (14% seq., 11% YoY); FY2022 est. $50.2M (20% YoY).
Preliminary cash and equivalents $102.3M as of Dec 31, 2022; sufficient to fund operations through mid-2024.
OTX-TKI wet AMD Phase 1: 9- and 10-month data at Angiogenesis Feb 2023; potential Phase 2/3 start Q3 2023 subject to funding.
Phase 1 diabetic retinopathy trial initiated Dec 2022; OTX-TIC glaucoma Phase 2 top-line data expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2022 results: revenue net product revenue for the fourth quarter of 2022 is estimated to be $13.6 million.

Period: the quarter and year ended December 31, 2022
Revenue: net product revenue for the fourth quarter of 2022 is estimated to be $13.6 million
Result: preliminary results

Exact text from the filing

the Company disclosed in the Release preliminary estimates as to net product revenue for the quarter and year ended December 31, 2022 and cash and cash equivalents as of December 31, 2022.

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-001710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.